SREBF1 and metabolic dysfunction-associated steatotic liver disease: Mechanistically, this FX-loaded nanocarrier system downregulated key lipid synthesis enzymes, including FASN, ACC1, and SREBP-1, in NAFLD model mice, thereby inhibiting lipogenesis, reducing fat accumulation, and slowing NAFLD progression.